Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, Breast Cancer, vol.107, pp.85-91, 2016. ,
Good clinical practice recommendations for the use of PET/CT in oncology, Eur J Nucl Med Mol Imaging, 2019. ,
A phase 2 study of 16?-[ 18 F]-fluoro-17?-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC), Mol Imaging Biol, vol.16, pp.431-440, 2014. ,
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas, PLoS One, vol.11, p.158634, 201627. ,
Immunopositron emission tomography with Zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?, Front Pharmacol, vol.7, p.131, 2016. ,
First-in-human human epidermal growth factor receptor 2-targeted imaging using 89 Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast cancer, J Nucl Med, vol.59, pp.900-906, 2018. ,
Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning, N Engl J Med, vol.22, pp.1384-1386, 1978. ,
Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen, Cancer Res, vol.40, pp.2984-2992, 1980. ,
The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer, Int J Cancer, vol.47, pp.865-874, 1991. ,
Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma, Cancer, vol.89, pp.104-115, 2000. ,
Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer, J Clin Oncol, vol.35, pp.3338-3346, 2017. ,
Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ?3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC), San Antonio Breast Cancer Symposium, pp.4-8, 2018. ,
, , pp.2-11
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer, N Engl J Med, vol.380, pp.741-751, 2019. ,
Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J Nucl Med, vol.34, pp.1267-1273, 1993. ,
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA/anti-DTPA-indium bispecific antibody, J Nucl Med, vol.39, pp.1172-1178, 1998. ,
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy, J Clin Endocrinol Metab, vol.92, pp.4590-4597, 2007. ,
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci USA, vol.103, pp.6841-6846, 2006. ,
Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial, J Nucl Med, vol.57, pp.1505-1511, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01415668
Molecular imaging of radiolabeled bispecific T-cell engager 89Zr-Amg211 targeting cea-positive tumors, Clin Cancer Res, vol.24, pp.4988-4996, 2018. ,
Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy, Eur Radiol, vol.21, pp.2604-2617, 2011. ,
Comparative diagnostic accuracy of 18 F-FDG PET/CT for breast cancer recurrence, Breast Cancer, vol.9, pp.461-471, 2017. ,
Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography, Appl Radiat Isot, vol.76, pp.55-62, 2013. ,
Importance of CEA and CA15-3 during disease progression in metastatic breast cancer patients, Anticancer Res, vol.27, pp.1963-1968, 2007. ,
Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method, EJNMMI Res, vol.2, p.5, 2012. ,
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule, Cell, vol.57, pp.327-334, 1989. ,
Development of an imagingguided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results, Br J Cancer, vol.109, pp.934-942, 2013. ,